Apolipoprotein A-II (Apolipoprotein A2)

The second most abundant protein component of HIGH DENSITY LIPOPROTEINS or HDL. It has a high lipid affinity and is known to displace APOLIPOPROTEIN A-I from HDL particles and generates a stable HDL complex. ApoA-II can modulate the activation of LECITHIN CHOLESTEROL ACYLTRANSFERASE in the presence of APOLIPOPROTEIN A-I, thus affecting HDL metabolism.

Also Known As:

Networked: 312 relevant articles (6 outcomes, 43 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Higuchi, Keiichi: 14 articles (03/2015 - 09/2002)
2.	Mori, Masayuki: 12 articles (03/2015 - 09/2002)
3.	Fu, Xiaoying: 10 articles (08/2011 - 09/2002)
4.	Sawashita, Jinko: 9 articles (03/2015 - 03/2006)
5.	Zhang, Beiru: 7 articles (02/2015 - 07/2007)
6.	Naiki, Hironobu: 6 articles (02/2015 - 05/2004)
7.	Blanco-Vaca, Francisco: 6 articles (12/2005 - 04/2002)
8.	Qian, Jinze: 5 articles (03/2015 - 07/2007)
9.	Chan, Dick C: 5 articles (06/2012 - 07/2006)
10.	Watts, Gerald F: 5 articles (06/2012 - 07/2006)

Related Diseases

1.	Atherosclerosis 11/01/2001 - "Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein." 02/01/2013 - "We aimed to examine whether apo A-II plays any role in atherogenesis and, if so, to elucidate the mechanism involved. " 02/01/2013 - "Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits." 06/01/2012 - "There is no evidence, however, that selective therapeutic modification of apoA-II impacts on atherosclerosis and clinical outcomes. " 02/01/2006 - "Significant, positive associations were found between apoA-II and C-III (r=0.883, P<0.001) and between apoA-II and atherosclerosis (r=0.68, P<0.001). "
2.	Coronary Artery Disease (Coronary Atherosclerosis) 06/01/1993 - "Apolipoprotein A-II levels and coronary artery disease in subjects with and without diabetes: a study with use of a specific radioimmunoassay for apolipoprotein A-II." 08/01/2008 - "The apolipoprotein AII rs5082 variant is associated with reduced risk of coronary artery disease in an Australian male population." 10/30/2007 - "Apolipoprotein A-II is inversely associated with risk of future coronary artery disease." 06/01/1993 - "In subjects with diabetes, however, apo A-II levels are similar in the presence or absence of coronary artery disease." 06/01/1993 - "After adjustments were made for age and sex, however, apo A-II levels were no longer significantly different between subjects with diabetes who had and those who did not have coronary artery disease. "
3.	Amyloidosis 03/18/2014 - "Together, experimental and bioinformatics studies explain why the C-terminal extension in human apoA-II causes amyloidosis and why, unlike murine apoA-II, human apoA-II normally does not cause amyloidosis despite its unusually high sequence propensity for β-aggregation. " 02/24/2015 - "Here, we demonstrate that congenic mouse strains carrying type F apoA-II (APOA2F) protein, which contains four amino acid substitutions in the amyloidogenic regions of APOA2C, were absolutely resistant to amyloidosis, even after induction of amyloidosis by injection of AApoAII. " 02/24/2015 - "Mouse strains carrying type C apoA-II (APOA2C) protein exhibit a high incidence of severe systemic amyloidosis. " 03/18/2014 - "C-terminal extension in human apoA-II or point substitutions in murine apoA-II cause amyloidosis. " 03/18/2014 - "Hot spots in apolipoprotein A-II misfolding and amyloidosis in mice and men."
4.	Insulin Resistance 04/01/2003 - "More clinical studies are necessary to clarify the role of apolipoprotein A-II in well-characterized subsets of patients and in the insulin resistance syndrome." 03/01/2001 - "Studies with apolipoprotein A-II transgenic mice indicate a role for HDLs in adiposity and insulin resistance." 12/01/2004 - "Mechanisms mediating insulin resistance in transgenic mice overexpressing mouse apolipoprotein A-II." 04/01/2003 - "Apolipoprotein A-II: beyond genetic associations with lipid disorders and insulin resistance." 07/01/2002 - "Evaluation of apolipoprotein A-II as a positional candidate gene for familial Type II diabetes, altered lipid concentrations, and insulin resistance."
5.	Hypertriglyceridemia 12/01/2006 - "Postprandial hypertriglyceridemia and low plasma HDL levels, which are principal features of the metabolic syndrome, are displayed by transgenic mice expressing human apolipoprotein A-II (hapoA-II). " 04/30/2002 - "On the mechanisms by which human apolipoprotein A-II gene variability relates to hypertriglyceridemia." 02/01/1998 - "Association between apolipoprotein A2 MspI polymorphism and hypertriglyceridemia in Koreans." 09/01/2007 - "This finding may partially explain the role of Apo A-II in lipid metabolism and can identify a population with a decreased risk of cardiovascular disease, as corresponds to the lower level of postprandial hypertriglyceridemia." 04/01/2002 - "Overexpression of human apolipoprotein A-II (hapo A-II) in transgenic mice (hAIItg mice) induced marked hypertriglyceridemia and low levels of plasma high density lipoprotein (HDL) with a high hapo A-II content. "

Related Drugs and Biologics

1.	Apolipoprotein A-I (Apolipoprotein A1)
2.	Lipoproteins (Lipoprotein)
3.	Proteins (Proteins, Gene)
4.	Apolipoproteins E (ApoE)
5.	Messenger RNA (mRNA)
6.	Apoproteins
7.	Apolipoproteins A
8.	Apolipoproteins
9.	HDL Cholesterol
10.	Apolipoprotein A-II (Apolipoprotein A2)

Related Therapies and Procedures

1.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
2.	Fat-Restricted Diet (Diet, Fat Restricted)
3.	Transplants (Transplant)
4.	Kidney Transplantation
5.	Ovariectomy (Oophorectomy)